HERC2P3: A Potential Cancer Treatment Target (G283755)

Target Name: HERC2P3

NCBI ID: G283755

HERC2P3

Other Name(s): HERC2 pseudogene 3 | D15F37S4

HERC2P3: A Potential Cancer Treatment Target

HERC2P3, also known as HERC2 pseudogene 3, is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer. The gene was first identified in 2009 and has since been shown to be involved in the development and progression of several types of cancer, including breast, ovarian, and prostate cancer.

The HERC2P3 gene is located on the X chromosome and is responsible for the production of a protein known as HEPARIN-related proteoglycan (HSPG) 63, which is a type of glycoprotein that is expressed in various tissues throughout the body. HSPG 63 has been shown to play a role in the development and progression of cancer by promoting the growth and survival of cancer cells.

In addition to its role in cancer development, HERC2P3 has also been shown to be involved in the regulation of cellular processes that are important for cell survival. For example, the gene has been shown to be involved in the regulation of cell adhesion, a process that is critical for the formation of tissues and organs.

Given its involvement in the development and progression of cancer, as well as its role in cell regulation, HERC2P3 is a promising candidate for drug targeting or biomarker research. Researchers are currently working to identify small molecules that can inhibit the activity of HERC2P3 and prevent its progression to cancer. These compounds may have the potential to be used as anti-cancer drugs or to serve as biomarkers for the detection and treatment of cancer.

In addition to its potential as a drug target or biomarker, HERC2P3 is also of interest to researchers because of its location on the X chromosome. Many diseases that affect women, such as breast cancer, are caused by changes in the X chromosome that result in the development of cancer. Therefore, studying the HERC2P3 gene and its role in the development and progression of these diseases could lead to new insights into the treatment of these conditions.

Overall, HERC2P3 is a gene that has the potential to be a drug target or biomarker for the treatment of various diseases, including cancer. Further research is needed to fully understand its role in these processes and to develop effective treatments based on its properties.

Protein Name: HERC2 Pseudogene 3

The "HERC2P3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HERC2P3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets